Champions Oncology (NASDAQ:CSBR) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Shares of Champions Oncology, Inc. (NASDAQ:CSBR) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.32 and traded as low as $5.65. Champions Oncology shares last traded at $5.65, with a volume of 895 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Champions Oncology Trading Down 1.9%

The stock has a market capitalization of $78.46 million, a PE ratio of -35.31 and a beta of 0.41. The stock’s fifty day simple moving average is $5.95 and its 200-day simple moving average is $6.32.

Hedge Funds Weigh In On Champions Oncology

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 6,229 shares during the last quarter. Mink Brook Asset Management LLC purchased a new position in Champions Oncology during the 4th quarter worth $555,000. Acadian Asset Management LLC boosted its holdings in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 8,814 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Champions Oncology in the 1st quarter worth about $201,000. Finally, Jane Street Group LLC purchased a new position in shares of Champions Oncology in the 1st quarter worth about $200,000. 41.30% of the stock is owned by hedge funds and other institutional investors.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.